Adjuvant and neoadjuvant therapy for primary GIST

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue SUPPL. 1, 2011, Pages

  Eisenberg, Burton L ^a   Smith, Kerrington D ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant therapy; Neoadjuvant therapy; Primary GIST; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HUMAN; METASTASIS; MITOSIS RATE; NONHUMAN; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 79151482280     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1516-5     Document Type: Article

References (33)

1. EH Ng, et al. 1992 Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging Ann Surg 215 1 68 77 1:STN:280:DyaK387hslOntw%3D%3D 10.1097/00000658- 199201000-00010 1731651
2. RP DeMatteo, et al. 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 1 51 58 1:STN:280:DC%2BD3c7gtVSmtQ%3D%3D 10.1097/00000658-200001000-00008 10636102
3. JP Pierie, et al. 2001 The effect of surgery and grade on outcome of gastrointestinal stromal tumors Arch Surg 136 4 383 389 1:STN:280: DC%2BD3M3kvVemsA%3D%3D 10.1001/archsurg.136.4.383 11296107
4. JA Crosby, et al. 2001 Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database Ann Surg Oncol 8 1 50 59 1:STN:280:DC%2BD3M7lsFeksg%3D%3D 10.1007/s10434-001-0050-4 11206225
5. CD Fletcher, et al. 2002 Diagnosis of gastrointestinal stromal tumors: a consensus approach Int J Surg Pathol 10 2 81 89 10.1177/106689690201000201 12075401
6. M Miettinen J Lasota 2006 Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 2 70 83 10.1053/j.semdp.2006. 09.001 17193820
7. T Takahashi, et al. 2007 An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors Int J Clin Oncol 12 5 369 374 1:CAS:528:DC%2BD2sXhtFGgsb7L 10.1007/s10147-007-0705-7 17929119
8. H Maeda, et al. 1992 Requirement of c-kit for development of intestinal pacemaker system Development 116 2 369 375 1:CAS:528:DyaK3sXls12msw%3D%3D 1283735
9. K Isozaki, et al. 1995 Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats Gastroenterology 109 2 456 464 1:CAS:528:DyaK2MXntlCgtLo%3D 10.1016/0016- 5085(95)90333-X 7542218
10. T Furitsu, et al. 1993 Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product J Clin Invest 92 4 1736 1744 1:CAS:528:DyaK2cXivVCntQ%3D%3D 10.1172/JCI116761 7691885
11. H Nagata, et al. 1995 Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder Proc Natl Acad Sci USA 92 23 10560 10564 1:CAS:528:DyaK2MXptlSjt70%3D 10.1073/pnas.92.23.10560 7479840
12. S Hirota, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 5350 577 580 1:CAS:528: DyaK1cXotVyhsw%3D%3D 10.1126/science.279.5350.577 9438854
13. M Taniguchi, et al. 1999 Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors Cancer Res 59 17 4297 4300 1:CAS:528: DyaK1MXlvVSms7o%3D 10485475
14. H Joensuu, et al. 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 14 1052 1056 1:STN:280:DC%2BD3M3gvVekuw%3D%3D 10.1056/NEJM200104053441404 11287975
15. GD Demetri, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 472 480 1:CAS:528:DC%2BD38XmtV2nt7s%3D 10.1056/NEJMoa020461 12181401
16. AT van Oosterom, et al. 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 9291 1421 1423 10.1016/S0140-6736(01)06535-7 11705489
17. CD Blanke, et al. 2008 Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 4 620 625 1:CAS:528:DC%2BD1cXis1alsL0%3D 10.1200/JCO.2007.13.4403 18235121
18. MC Heinrich, et al. 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 5607 708 710 1:CAS:528:DC%2BD3sXntFWitQ%3D%3D 10.1126/science.1079666 12522257
19. MC Heinrich, et al. 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 23 4342 4349 1:CAS:528:DC%2BD2cXpsVWqu7Y%3D 10.1200/JCO.2003.04.190 14645423
20. CR Antonescu, et al. 2005 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 11 4182 4190 1:CAS:528:DC%2BD2MXks1GksLw%3D 10.1158/1078-0432.CCR- 04-2245 15930355
21. JR Zalcberg, et al. 2005 Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg Eur J Cancer 41 12 1751 1757 1:CAS:528: DC%2BD2MXns1Wit7g%3D 10.1016/j.ejca.2005.04.034 16098458
22. GD Demetri, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 1329 1338 1:CAS:528: DC%2BD28XhtVOrtL%2FL 10.1016/S0140-6736(06)69446-4 17046465
23. VL Goodman, et al. 2007 Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin Cancer Res 13 5 1367 1373 1:CAS:528: DC%2BD2sXitlSjsbc%3D 10.1158/1078-0432.CCR-06-2328 17332278
24. R DeMatteo K Ballman C Antonescu, et al. 2009 Adjuvant Imatinib Mesylate after resection of localized primary gastrointestinal stromal tumor: a randomized double blind placebo controlled trial Lancet 373 1097 1104 1:CAS:528:DC%2BD1MXjslOltro%3D 10.1016/S0140-6736(09)60500-6 19303137
25. JY Blay, et al. 2007 Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol 25 9 1107 1113 1:CAS:528:DC%2BD2sXksVyrs7s%3D 10.1200/JCO.2006.09.0183 17369574
26. S Singer, et al. 2002 Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors J Clin Oncol 20 18 3898 3905 1:CAS:528:DC%2BD38XntVynsLo%3D 10.1200/JCO.2002.03.095 12228211
27. J Gold M Gonen J Gutierrez, et al. 2009 Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localized primary gastroinestinal stromal tumor-a retrospective analysis Lancet Oncol 10 1045 1052 10.1016/S1470-2045(09)70242-6 19793678
28. PG Casali L Jost P Reichardt M Schlemmer JY Blay 2009 Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and followup Ann Oncol 20 4 64 67 19454466
29. NCCN. The NCCN soft tissue sarcoma clinical practice guidelines in oncology. (version 1.2009). (C) 2009 National Comprehensive Cancer Network, Inc
30. B Eisenberg I Judson 2004 Surgery and Imatinib in the management of GIST. Emerging approaches to adjuvant and neoadjuvant therapy Ann Surg Oncol II 5 465 475 10.1245/ASO.2004.09.011
31. B Eisenberg J Harris C Blanke G Demetri, et al. 2009 Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary, metastatic/recurrent operable GIST-early results of RTOG J Surg Oncol 99 1 42 47 1:CAS:528:DC%2BD1MXhvFCjur0%3D 10.1002/jso.21160 18942073
32. R Andtbacka C Ng C Scaife J Cormier, et al. 2007 Surgical resection of Gastrointestinal Stromal Tumor after treatment with Imatinib Ann Surg Oncol 14 1 14 24 10.1245/s10434-006-9034-8 17072676
33. C Raut M Posner J Desai, et al. 2006 Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2325 2331 1:CAS:528:DC%2BD28XlvV2ksbw%3D 10.1200/JCO.2005.05.3439 16710031